

**Sensibilitat *Mycobacterium*
tuberculosis als antimicobacterians.**

2002-2018 HSCSP

2002-2007

Antecedents de tractament	TOTAL	Pacients nous			Pacients prèviament tractats			Antecedents de tractament desconeguts		
		total	espanyols	estrangers	total	espanyols	estrangers	total	espanyols	estrangers
	347	280	217	63	34	24	10	33	24	9
sensibles	325 (93,7)	262 (93,6%)	206 (94,9%)	56 (88,9%)	30 (88,2%)	24 (100%)	6 (60%)	33	24	9
resistents	22 (6,3%)	18 (6,4%)	11 (5,1%)	7 (11,1%)	4 (11,8%)	0	4 (40%)	0	0	0
Isoniazida	17 (4,89%)	15 (5,4%)	11 (5,06%)	4 (6,34%)	2 (5,9%)	0	2 (20%)			
Rifampicina	3 (0,8%)	2 (0,7%)	0	2 (3,2%)	1 (2,9%)	0	1 (10%)			
Etambutol	1 (0,3%)	0	0	0	1 (2,9%)	0	1 (10%)			
Estreptomicina	9 (2,6%)	6 (2,2%)	1 (0,5%)	5 (7,9%)	3 (8,8%)	0	3 (30%)			
Pirazinamida	5 (1,4%)	4 (1,4%)	2 (0,9%)	2 (3,2%)	1 (2,9%)	0	1 (10%)			
MDR	2 (0,6%)	1 (0,4%)	0	1 (1,6%)	1 (2,9%)	0	1 (10%)			

2008-2011

Antecedents de tractament	TOTAL	Pacients nous			Pacients prèviament tractats			Antecedents de tractament desconeguts		
		total	espanyols	estrangers	total	espanyols	estrangers	total	espanyols	estrangers
	188	154	88	66	11	6	5	23	17	6
sensibles	145 (77,1%)	121 (78,6%)	81 (93,1%)	40 (60,6%)	6 (54,5%)	3 (50%)	3 (60%)	18 (78,3%)	14 (82,4%)	4 (66,6%)
resistents	43(22,9%)	33 (21,4%)	7 (6,9%)	26 (39,4%)	5 (45,5%)	3 (50%)	2 (40%)	5 (21,7%)	3 (17,6%)	2 (33,4%)
Isoniazida	20 (10,6%)	15 (9,7%)	3 (3,4%)	12 (18,2%)	2 (18,1%)	1 (16,6%)	1 (20%)	3 (13%)	2 (11,8%)	1 (16,6%)
Rifampicina	5 (2,65%)	4 (2,6%)	0	4 (6,1%)	1 (9%)	1 (16,6%)	0	0	0	0
Etambutol	3 (1,9%)	3 (1,9%)	1 (1,1%)	2 (3%)	0	0	0	0	0	0
Estreptomicina	10 (5,3%)	7 (4,5%)	3 (3,4%)	4 (6,1%)	1 (9%)	1 (16,6%)	0	2 (8,7%)	1 (5,9%)	1 (16,6%)
Pirazinamida	9 (4,8%)	6 (3,9%)	1 (1,1%)	5 (7,5%)	3 (27,3%)	2 (33,3%)	1 (20%)	0	0	0
MDR	3 (1,6%)	3 (1,9%)	0	3 (4,5%)	0	0	0	0	0	0

2012-2018

Antecedents de tractament	TOTAL	Pacients nous			Pacients prèviament tractats			Antecedents de tractament desconeguts		
		total	espanyols	estrangers	total	espanyols	estrangers	total	espanyols	estrangers
	178	108	57	51	22	12	10	48	32	16
sensibles	160 (89.9%)	97 (89.8%)	53 (92.9%)	44 (86.3%)	20 (90.9%)	11 (91.6%)	9 (90%)	43 (89,6%)	28 (87,5%)	15 (93,7%)
resistents	18 (10.1%)	11(10.2%)	4 (7.1%)	7 (13.7%)	2 (9.1%)	1 (8.4%)	1 (10%)	5 (10,4%)	4 (12,5%)	1 (6,3%)
Isoniazida	14 (7.8%)	9 (8.3%)	3 (5.3%)	6 (11.8%)	3 (13.6%)	1 (8.3%)	2 (20%)	2 (4,2%)	1 (3,1%)	1 (6,2%)
Rifampicina	5 (2.8%)	3 (2.7%)	0	3 (5.8%)	2 (9.1%)	1 (8.3%)	1 (10%)	0	0	0
Etambutol	4 (2.2%)	2 (1.8%)	1 (1.7%)	1 (2%)	1 (4.5%)	0	1 (10%)	1(2,1%)	1 (3,1%)	0
Estreptomicona	7 (3.9%)	4 (3.7%)	1 (1.7%)	3 (5.8%)	1 (4.5%)	1 (8.3%)	0	2 (4,2%)	2 (6,2%)	0
Pirazinamida	2 (1.1%)	1 (0.9%)	0	1 (2%)	1 (4.5%)	0	1 (10%)	0	0	0
MDR	4 (2.25%)	2 (1.8%)		2 (3.9%)	2 (9.1%)	1 (8.3%)	1 (10%)	0	0	0

2002-2018

Antecedents de tractament	TOTAL	Pacients nous			Pacients prèviament tractats			Antecedents de tractament desconeguts		
		total	espanyols	estrangers	total	espanyols	estrangers	total	espanyols	estrangers
	713	542	362	180	67	42	25	104	73	31
sensibles	632 (88.6%)	480 (88.6%)	340 (94%)	140 (77.8%)	56 (85.1%)	38 (90.5%)	18 (72%)	96 (92,3%)	68 (93,1%)	28 (90,3%)
resistents	81 (11.4%)	62 (11.4%)	22 (6%)	40 (22.2%)	11 (14.9%)	4 (9.5%)	7 (28%)	8 (7,7%)	5 (6,9%)	3 (9,7%)
Isoniazida	51 (7.2%)	39 (7.2%)	17 (4.7%)	22 (12.2%)	7 (10.4%)	2 (4.8%)	5 (20%)	5 (4,7%)	3 (4,1%)	2 (6,45%)
Rifampicina	12 (1.7%)	9 (1.7%)	0	9 (5%)	4 (6%)	2 (4.8%)	2 (8%)	0	0	0
Etambutol	7 (0.9%)	5 (0.9%)	2 (0.5%)	3 (1.7%)	2 (3%)	0	2 (8%)	0	0	0
Estreptomicona	27 (3.8%)	17 (3.1%)	5 (1.4%)	12 (6.7%)	5 (7.5%)	2 (4.8%)	3 (12%)	4 (3,8%)	3 (4,1%)	1 (3,2%)
Pirazinamida	17 (2.4%)	11 (2.3%)	3 (0.8%)	9 (5%)	5 (7.5%)	2 (4.8%)	3 (12%)	0	0	0
MDR	9 (1.3%)	6 (1.1%)	0	6 (1.1%)	3 (4.5%)	1 (2.4%)	2 (8%)	0	0	0